. Author manuscript; available in PMC: 2021 Feb 3.

Published in final edited form as: Nat Biomed Eng. 2020 Aug 3;4(11):1030–1043. doi: 10.1038/s41551-020-0594-x

Table 1:

Summary of binding and functional activities of 20 characterized lead mAbs.

mAb clone	B cell isolation method	ELISA binding to recombinant E (Yes/No)	Epitope specificity	ZIKV neutralization RTCA IC₅₀ (ng/mL)		IgG prophylaxis, % survival (9 μg dose)	IgG therapy, % survival (9 μg dose)	RNA delivery, % survival
mAb clone	B cell isolation method	ELISA binding to recombinant E (Yes/No)	Epitope specificity	Dakar	Brazil	IgG prophylaxis, % survival (9 μg dose)	IgG therapy, % survival (9 μg dose)	RNA delivery, % survival
ZIKV-423	ND	Y	DIII	>3,000	305	ND	0	40
ZIKV-434	ND	—	ND	112	308	ND	ND	100
ZIKV-518	Sub-panel 1	Y	DIII	>3,000	59	ND	ND	0
ZIKV-608	Sub-panel 1	Y	DIII	>3,000	118	ND	ND	0
ZIKV-609	Sub-panel 1	Y	DII^*	204	125	40	ND	100
ZIKV-624	Sub-panel 2	—	ND	689	190	60	ND	100
ZIKV-635	Sub-panel 2	Y	ND	90	171	100	ND	100
ZIKV-652	Sub-panel 2	Y	DII	309	192	ND	ND	100
ZIKV-668	Sub-panel 2	—	ND	128	195	100	ND	100
ZIKV-681	Sub-panel 2	Y	DIII	>3,000	420	ND	ND	40
ZIKV-682	Sub-panel 1	Y	ND	221	204	ND	ND	80
ZIKV-684	Sub-panel 1	Y	DIII	60	214	ND	ND	100
ZIKV-752	Sub-panel 1	Y	DIII^*	7	12	79	60	80
ZIKV-869	Sub-panel 1	—	DII^*	283	215	80	ND	40
ZIKV-893	Sub-panel 2	—	DII^*	38	58	100	100	100
ZIKV-922	Sub-panel 2	Y	DIII	>3,000	235	ND	ND	0
ZIKV-940	Sub-panel 3	Y	DI/II^*	22	52	69	100	100
ZIKV-980	Sub-panel 3	Y	DIII^*	101	45	0	ND	20
ZIKV-1006	Sub-panel 3	Y	DII^*	128	138	20	ND	0
ZIKV-1007	Sub-panel 3	Y	ND	1,100	426	ND	ND	0
ZIKV-117	N/A	Y	DII	8	7	100	80	100

Potent cross-neutralizing mAbs of several epitope specificities that revealed high protection in vivo are indicated with bold font. The “*” symbol indicates epitope specificity that was mapped precisely by a shotgun mutagenesis that shows loss of mAb binding to specific mutant E proteins (see Methods). ND – not determined.